Treatment of PCOS with metformin and other insulin-sensitizing agents

Current Diabetes Reports

Volumn 4, Issue 1, 2004, Pages 69-75

  Seli, Emre ^a   Duleba, Antoni J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CLOMIFENE CITRATE; INOSITOL DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; ANTIDIABETIC AGENT; INOSITOL PHOSPHATE; INOSITOL PHOSPHATE GLYCAN; POLYSACCHARIDE;

ANEMIA; ANOVULATION; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; EDEMA; FEMALE; FEMALE INFERTILITY; FETUS DEATH; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; OVULATION; REVIEW; SPONTANEOUS ABORTION; WEIGHT GAIN;

FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL PHOSPHATES; METFORMIN; POLYCYSTIC OVARY SYNDROME; POLYSACCHARIDES; THIAZOLIDINEDIONES;

EID: 1642415794     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0014-8     Document Type: Review

References (76)

1. Stein IF, Leventhal ML: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29: 181-191.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al.: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83: 3078-3082.
3. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al.: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006-4011.
4. Asuncion M, Calvo RM, San Millan JL, et al.: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85: 2434-2438.
5. Hull MGR: Epidemiology of infertility and polycystic ovarian disease: endocrinologic and demographic studies. Gynecol Endocrinol 1987, 1: 235-245.
6. Adams J, Polson DW, Franks S: Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986, 293: 355-359.
7. Dunaif A, Graf M, Mandeli J, et al.: Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987, 65: 499-507.
8. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84: 165-169.
9. National Institute of Health. Third Report on the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III NIH Publication 01-3670. Bethesda, MD: National Institutes of Health; 2001.
10. Haffner SM, Valdez RA, Hazuda HP, et al.: Prospective analysis of the insulin-resistance syndrome (syndrome X . Diabetes 1992, 41: 715-722.
11. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24: 683-689.
12. Trevisan M, Liu J, Bahsas FB, Menotti A: Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998, 148: 958-966.
13. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287: 356-359.
14. Glueck CJ, Papanna R, Wang P, et al.: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab Clin Exp 2003, 52: 908-915.
15. Dahlgren E, Johansson S, Lindsted G, et al.: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992, 57: 505-513.
16. Attia GR, Rainey WE, Carr BR: Metformin directly inhibits androgen production in human theca cells. Fertil Steril 2001, 76: 517-524.
17. Duleba AJ, Pawelczyk LA, Yuen HB, Moon YS: Insulin actions on ovarian steroidogenesis are not modulated by metformin. Hum Reprod 1993, 8: 1194-1198.
18. Velazquez EM, Mendoza S, Hamer T, et al.: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp 1994, 43: 647-654.
19. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome p450c1alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335: 617-623.
20. Velazquez E, Acosta A, Mendoza SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997, 90: 392-395.
21. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998, 138: 269-274.
22. Morim-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998, 69: 691-696.
23. Unluhizarci K, Kelestimur F, Bayram F, et al.: The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol 1999, 51: 231-236.
24. Glueck CJ, Wang P, Fontaine R, et al.: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999, 48: 511-519.
25. Pirwany IR, Yates RWS, Cameron IT, Fleming R: Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhea. Hum Reprod 1999, 14: 2963-2968.
26. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L: Metformin therapy improves hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000, 73: 1149-1154.
27. Moghetti P, Castello R, Negri C, et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85: 139-146.
28. Fleming R, Hopkinson ZE, Wallace AM, et al.: Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2002, 87: 569-574.
29. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance , independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38: 1165-1174.
30. Mather KJ, Kwan F, Corenblum B: Hyperinsulinemia in polycystic ovarian syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 1999, 73: 150-156.
31. Nestler JE, Jakubowicz DJ: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian p450c17alpha activity and serum androgens. J Clin Endocrinol Metab 1997, 82: 4075-4079.
32. Crave JC, Fimbel S, Lejeune H, et al.: Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995, 80: 2057-2062.
33. Acbay O, Gundogdu S: Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996, 65: 946-949.
34. Ehrmann DA, Cavaghan MK, Imperial J, et al.: Effects of Metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82: 524-530.
35. Ng EH, Wat NM, Ho PC: Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001, 16: 1625-1631.
36. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998, 338: 1876-1880.
37. Vandermolen DT, Ratts VS, Evans WS, et al.: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001, 75: 310-315.
38. De Leo V, la Marca A, Ditto A, et al.: Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999, 72: 282-285.
39. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM: Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of insulin-like growth factors. Fertil Steril 2001, 75: 505-509.
40. Ibanez L, Valls C, Potau N, et al.: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000, 85: 3526-3530.
41. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al.: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 524-529.
42. Regan L, Braude PR, Trembath PL: Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989, 299: 541-545.
43. Glueck CJ, Phillips H, Cameron D, et al.: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001, 75: 46-52.
44. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L: Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002, 17: 2858-2864.
45. Coetzee EJ, Jackson WP: Oral hypoglycemics in the first trimester and fetal outcome. S Afr Med J 1984, 65: 635-637.
46. Wild RA, Painter PC, Coulson PB, et al.: Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985, 61: 946-951.
47. Talbott E, Guzick D, Clerici A, et al.: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995, 15: 821-826.
48. Dahlgren E, Janson PO, Joharisson S, et al.: Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994, 61: 455-460.
49. Talbott EO, Zborowski JV, Guzick DS, et al.: Increased PAI-1 levels in women with polycystic ovary syndrome: Evidence for a specific "PCOS" effect independent of age and BMI. Programs and Abstracts of the 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association. San Diego, CA; 2000.
50. Zimmermann S, Phillips RA, Dunaif A, et al.: Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992, 75:508-513.
51. Talbott EO, Guzick DS, Sutton-Tyrell K, et al.: Evidence for an association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20: 2414-2421.
52. Festa A, D'Agostino R Jr, Tracy RP, et al.: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51: 1131-1137.
53. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342: 836-843.
54. Kelly CC, Lyall H, Petrie JR, et al.: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001, 86: 2453-2455.
55. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years [no authors listed]. BMJ 1995, 310: 83-88.
56. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352: 854-865.
57. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L: Metformin improves lipid profile in hyperinsulinemic women with polycystic ovary syndrome. Paper presented at the 46th Annual Meeting of the Society for Gynecologic Investigation. Toronto, Canada; 1999.
58. Velazquez EM, Mendoza SG, Wang P, Glueck CJ: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metab Clin Exp 1997, 46:454-457.
59. Legro RS: Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001, 28:99-109.
60. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group [no authors listed]. N Engl J Med 2002, 346: 393-403.
61. Lebovitz HE: Differentiating members of thiazolidine class: a focus on safety. Diabetes Metab Res Rev 2002, 18: S23-S29.
62. Dunaif A, Scott D, Finegood D, et al.: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81: 3299-3306.
63. Hasegawa I, Murakawa H, Suzuki M, et al.: Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999, 71: 323-327.
64. Mitwally MF, Kuscu NK, Yalcinkaya TM: High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999, 14: 2700-2703.
65. Azziz R, Ehrmann DA, Legro RS, et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2001, 86: 1626-1632.
66. Shobokshi A, Shaarawy M: Correction of insulin resistance and hyperandrogenism in polycystic ovarian syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003, 10: 99-104.
67. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al.: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003, 79: 562-566.
68. Salzman A, Patel J: Rosiglitazone therapy is not associated with hepatotoxicity. Diabetes 1999, 48: A98.
69. Romualdi D, Guido M, Ciampelli M, et al.: Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinemic obese patients with polycystic ovarian syndrome. Hum Reprod 2003, 18: 1210-1218.
70. Glueck CJ, Moreira A, Goldenberg N, et al.: Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003, 18: 1618-1625.
71. May L, Lefkowich J, Kram M, Rubin D: Mixed hepatocellular cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002, 136: 449-452.
72. Maeda K: Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2001, 135: 306.
73. Larner J: Multiple pathways in insulin signaling: fitting the covalent and allosteric puzzle pieces together. Endocr J 1994, 2: 167-171.
74. Ortmeyer HK, Bodkin NL, Lilley K, et al.: Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology 1993, 132: 640-645.
75. Asplin I, Galasko G, Larner J: Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A 1993, 90: 5924-5928.
76. Nestler JE, Jakubowicz DJ, Reamer P, et al.: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999, 340: 1314-1320.